Glucagonoma CT

Revision as of 22:32, 30 May 2019 by Ahmed Younes (talk | contribs) (→‎CT)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Glucagonoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Glucagonoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucagonoma CT On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucagonoma CT

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucagonoma CT

CDC on Glucagonoma CT

Glucagonoma CT in the news

Blogs on Glucagonoma CT

Directions to Hospitals Treating Glucagonoma

Risk calculators and risk factors for Glucagonoma CT

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

Findings on abdominal CT scan suggestive of glucagonoma include a reinforced mass in the arterial phase of the enhanced CT scan. Symptomatic but non functioning glucagonomas are usually large (>3 cm) at the time of diagnosis.

CT

The CT scan findings associated with glucagonoma include:[1][2][3][4][5]

  • CT scans are used to determine the location of the tumor, show the organs nearby, determining the stage of cancer and in determining whether surgery is a good treatment option.
  • Spiral multi phasic contrast-enhanced CT is recommended.
  • Sensitivity is greater than 80 percent but it is decreased for tumors smaller than 2 cm.
  • With contrast, glucagonomas often enhance with iodinated contrast during the early arterial phase with washout during the portal venous imaging phase.
  • Liver metastases may appear isodense with the liver on a non-contrasted study.
  • Symptomatic but nonfunctioning glucagonomas are usually large (>3 cm) at the time of diagnosis.

References

  1. Lv WF, Han JK, Liu X, Wang SC, Pan BO, Xu AO (2015). "Imaging features of glucagonoma syndrome: A case report and review of the literature". Oncol Lett. 9 (4): 1579–1582. doi:10.3892/ol.2015.2930. PMC 4356379. PMID 25789004.
  2. Khashab MA, Yong E, Lennon AM, Shin EJ, Amateau S, Hruban RH; et al. (2011). "EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors". Gastrointest Endosc. 73 (4): 691–6. doi:10.1016/j.gie.2010.08.030. PMID 21067742.
  3. Paulson EK, McDermott VG, Keogan MT, DeLong DM, Frederick MG, Nelson RC (1998). "Carcinoid metastases to the liver: role of triple-phase helical CT". Radiology. 206 (1): 143–50. doi:10.1148/radiology.206.1.9423664. PMID 9423664.
  4. Legmann P, Vignaux O, Dousset B, Baraza AJ, Palazzo L, Dumontier I; et al. (1998). "Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography". AJR Am J Roentgenol. 170 (5): 1315–22. doi:10.2214/ajr.170.5.9574609. PMID 9574609.
  5. Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS; et al. (2010). "Identification of unknown primary tumors in patients with neuroendocrine liver metastases". Arch Surg. 145 (3): 276–80. doi:10.1001/archsurg.2010.10. PMID 20231629.

Template:WH Template:WS